Comparison of the Effectiveness and Safety of the Oral Selective Inhibitor of Nuclear Export, Selinexor, in Diffuse Large B Cell Lymphoma Subtypes

Autor: Jatin P. Shah, Andre Goy, John Kuruvilla, Joost S.P. Vermaat, Eric Van Den Neste, Catherine Thieblemont, Sameer Bakhshi, Miguel Canales, Michael Kauffman, Sharon Shacham, Nagesh Kalakonda, Ulrich Jaeger, Theodoros P. Vassilakopoulos, Krzysztof Warzocha, Marie Maerevoet, Kamal Chamoun, René-Olivier Casasnovas, Juan-Manuel Sancho, Fatima De la Cruz, Sylvain Choquet, Fritz Offner, Matthew Ku, Ronit Gurion, George A Follows, Josee M. Zijlstra, Miklos Egyed, Xiwen Ma, Federica Cavallo, Paolo Caimi, Brian T. Hill, Priyanka Samal, Michael W. Schuster, Nada Hamad

Publikováno v: Clinical Lymphoma Myeloma & Leukemia
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
Clinical lymphoma, myeloma & leukemia, Vol. 22, no.1, p. 24-33 (2022)
Clinical Lymphoma, Myeloma and Leukemia, 22(1), 24-33. CIG MEDIA GROUP, LP

The phase 2b, open-label, multicenter SADAL study evaluated single agent oral selinexor, a selective inhibitor of nuclear export (SINE) compound, in patients with diffuse large B cell lymphoma (DLBCL) after >= 2 lines of systemic therapy. Similar act

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0134fecc74cd5c013bf6038ffe02ab6b
https://fundanet.igtp.cat/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=5259